Expert Interview
A Second Opinion: Discussing the potential of Biohaven Pharmaceutical's troriluzole, a tripeptide prodrug formulation of riluzole taken orally to treat OCD, which has recently failed it's phase 2/3 trial.
Ticker(s): BHVNInstitution: Private Practice
- Manages 50 with Schizophrenia; 30 patients with Ingrezza
- Familiar with the data for KarXT (xanomeline-trospium) a M1/M4- preferring muscarinic agonist being investigated for treatment in patients with Schizophrenia
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
